VIP may push renal cancer cells toward autophagy and cell death (preclinical)

Vasoactive intestinal peptide (VIP) is an endogenous neuropeptide best known for roles in smooth muscle relaxation, vasodilation, and immune modulation. A new preclinical study reports something different: VIP may also trigger autophagy and cytotoxicity in renal cell carcinoma (RCC) models, via signaling that the authors link to SIRT3.

Study: Journal of Biochemical and Molecular Toxicology (2026). https://pubmed.ncbi.nlm.nih.gov/41891524/ (DOI: https://doi.org/10.1002/jbt.70815)

What they did (high level)

From the abstract-level view, the authors tested VIP in RCC experimental systems and looked at:

• cell viability / cytotoxicity outcomes
• autophagy-associated readouts
• a mechanistic pathway model centered on SIRT3

What changed / what is new

The new claim is not “VIP is a cancer drug.” It is narrower:

• VIP can induce autophagy-related signaling in these RCC models
• VIP treatment is associated with reduced viability / cytotoxicity
• the authors propose the effect depends on SIRT3-associated signaling

If this holds up, it adds to the (already complicated) story that neuropeptides can sometimes act as growth factors in some contexts and stress signals in others.

Why it might matter

Renal cell carcinoma has a long history of “interesting mechanisms” that do not translate. Still, there are a couple of reasons this is worth logging:

• VIP is a native peptide with well-studied receptors and physiology.
• Autophagy is a double-edged process in cancer (sometimes protective, sometimes a route to death). Work that clarifies directionality in a defined model can be informative.
• SIRT3 sits in mitochondrial biology, which is increasingly relevant in cancer metabolism discussions.

What we know vs what we don’t know

What we know:

• This is a preclinical report linking VIP exposure to autophagy markers and cytotoxicity in RCC models.

What we don’t know:

• Whether the effect is reproducible across RCC subtypes, doses, and experimental conditions.
• Whether autophagy is a cause of cytotoxicity here, or a correlated stress response.
• Whether any of this translates to a meaningful therapeutic window in vivo.

Practical reality

VIP is not a cancer treatment. If this line of work progresses, the translational question will likely be about receptor targeting, delivery, and selectivity, not about anyone self-experimenting with VIP peptides.

Further reading

• Vasoactive Intestinal Peptide Induces Autophagy and Cytotoxicity in Renal Cell Carcinoma via SIRT3-Dependent Signaling Pathway. (2026) https://pubmed.ncbi.nlm.nih.gov/41891524/ (DOI: https://doi.org/10.1002/jbt.70815)

Related reading

• A peptide gel to help bladder cancer immunotherapy

  A mouse study reports an enzyme-responsive peptide that forms a bladder-local hydrogel depot to retain BCG longer, aiming to reduce washout and improve immune activation in non-muscle-invasive bladder cancer.

• A bicyclic peptide that targets a cancer integrin

  Researchers report a bicyclic peptide isomer (10‑Mansa) that selectively inhibits integrin αvβ6 and shows prolonged tumor enrichment in preclinical work, highlighting how 3D peptide shape can make or break targeting.

• Osteoarthritis isn’t just wear-and-tear. A ‘resolution’ peptide is one way to treat what’s left

  A 2026 mouse study reports that Ac2‑26, an Annexin A1–derived pro‑resolving peptide, reduced pain-like sensitivity and several joint damage readouts in collagenase-induced osteoarthritis. It’s preclinical—but it illustrates the logic of “resolution pharmacology.”

• A tiny amino acid tweak that can help peptides go oral

  A medicinal-chemistry study suggests one residue, Aib, can sometimes ‘pre-organize’ macrocyclic peptides so they cross membranes more easily, improving oral exposure in mice. It is scaffold-dependent, not magic.

Explore more

NewsCancerVIPAutophagy